Company intelligence / Profile preview

Geneseq Biosciences

Melbourne, Victoria, Australiageneseq.com.au ↗

Ownership: Private
Employees: ~3
Development stage: Commercial

Overview

Geneseq Biosciences has developed Melaseq™, a clinically validated, NATA-accredited genomic liquid biopsy test that detects the microRNA fingerprint of invasive melanoma from blood or tissue samples. The company leverages expertise in cancer biology, IVD assay design, scalable bioinformatics, and regulatory compliance to deliver precision oncology diagnostics. No published clinical trial results are cited; the product is described as "clinically validated" and available for use.

Therapeutic areas: Oncology
Modalities: Diagnostic test (liquid biopsy)Molecular diagnostics
Industry: Molecular Diagnostics

Drug pipeline

1 asset

Melaseq

Commercial

Indications: Melanoma

Partnerships

Clinical Labs Australia ("Now available for clinical use")

Beyond the preview

Go deeper on Geneseq Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Geneseq Biosciences.

Explore the full profile